ObjectiveGI Establishes 10th Gastroenterology “Center of Research Excellence”

ObjectiveGI Establishes 10th Gastroenterology “Center of Research Excellence,” Partnering with More Than 100 Physicians to Reach Thousands of Patients in the U.S.

Studies Show Increased Presence of Concurrent Type 2 Diabetes and NAFLD

An analysis of 80 worldwide studies shows the ever-growing prevalence of patients with both type two diabetes and nonalcoholic fatty liver disease. This prevalence varies in different regions of the globe.

NASH Leads Liver Disease “Economic Tsunami” in the US

A white paper presented by the University of Oxford’s visiting professor of hepatology, Dr. Stephen A. Harrison, examines the economic impact of the liver disease epidemic on the US healthcare system.

Phase II clinical trial shows promise for type 2 diabetes

Fantastic news out of Amsterdam University Medical Center! A phase II study has reported duodenal mucosal resurfacing has promising results for type 2 diabetes patients, showing lasting improvements for insulin resistance markers and glycemic control – all without bariatric surgery.

Combined tests help identify NASH-related fibrosis

Researchers at Newcastle University in the UK found that Fibrosis-4 indexes coupled with enhanced liver fibrosis tests can identify NASH-related advanced fibrosis while reducing indeterminate results rate. Take a look at their compelling study.

Studies show microbiome may contribute to all immune-related diseases

Multiple studies suggest that the gut microbiome likely contributes to all diseases caused by a dysregulation of the immune system – including obesity, diabetes, and NASH.

New ADA Recommendation

The American Diabetes Association is now recommending screening for liver fibrosis in patients with type 2 diabetes suspected of having nonalcoholic fatty liver disease.

Weight loss continues to be associated with clinically meaningful improvements

Weight loss continues to be associated with clinically meaningful improvements in biomarkers of nonalcoholic fatty liver disease.

New research aimed at developing a first-in-class dual agonist

New research aimed at developing a first-in-class dual agonist that targets all three key drivers of NASH – steatosis, inflammation, and fibrosis.

ObjectiveGI Collaborates with Clinical Research IO

ObjectiveGI Collaborates with Clinical Research IO to Launch eSource Direct Data Capture Research Capabilities at the Point-of-Care

New drug for treating fatty liver disease

A new drug for treating fatty liver disease is currently being reviewed by the FDA.

weight loss with ESG

Landmark research shows 15% sustainable weight loss with ESG which is associated with improvement in NASH, diabetes and cardiovascular disease.

Routine screening for NAFLD

Routine screening for NAFLD is recommended for type 2 diabetes patients.

cardiovascular disease risk in patients

There is evidence of cardiovascular disease risk in patients with NAFLD and type 2 diabetes.

Gut microbes eat our medication.

Fascinating early work on the role of the microbiome and drug metabolism.

18 million patients with NAFLD

A telling study of 18 million patients with NAFLD, and the associated risk of cirrhosis.